TOFA - C19H32O4 - Bertin Bioreagent

Confirm delete?

TOFA

Zoom

Cat No: 10005263

Biochemicals - Small Molecule Inhibitors

Inhibition of fatty acid synthase (FASN) by the irreversible inhibitor cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines.{11992} TOFA is an inhibitor of fatty acid synthesis blocking the synthesis of malonyl-CoA by acetyl-CoA car...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

5-(tetradecyloxy)-2-furancarboxylic acid

Correlated keywords:

inhibits inhibitors inhibition ACC acetyl-CoA carboxylases fatty acid synthases synthesis FAS cerulenin apoptosis cancer C75 malonyl-CoA atherosclerosis endocrinology

Product Overview:
Inhibition of fatty acid synthase (FASN) by the irreversible inhibitor cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines.{11992} TOFA is an inhibitor of fatty acid synthesis blocking the synthesis of malonyl-CoA by acetyl-CoA carboxylase (ACC).{7659} Both cerulenin (at about 10 µg/ml) and TOFA (at about 1 µg/ml) are effective at blocking the incorporation of radiolabeled acetate into palmitate. However, TOFA reduces malonyl-CoA levels rather than elevating them, and TOFA is relatively non-toxic to various cancer cell lines. TOFA also attenuates the inhibition of feeding observed when FASN inhibitors such as cerulenin and C75 are administered to obese ob/ob mice.

Size	5 mg
Shipping	dry ice
CAS Number	54857-86-2
Molecular Formula	C₁₉H₃₂O₄
SMILES	CCCCCCCCCCCCCCOc1ccc(o1)C(=O)O
Molecular Weight	324,5
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2932.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.